Attovia Therapeutics, Inc. ATTO
Attovia Therapeutics, Inc. (Nasdaq: ATTO) is an immunology/inflammation drug developer. Its lead program, ATTO-1310, is in Phase 1 for Chronic pruritus / high-itch atopic dermatitis (also CPUO, cholestatic pruritus, CKD-aP planned). Its next catalyst on record is ATTO-1310: Initiate Phase 2 clinical trial (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATTO-1310 — Initiate Phase 2 clinical trial (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATTO-1310 (anti-IL-31 ATTOBODY Fc-fusion) | Chronic pruritus, high-itch AD | protein/peptide | Phase 1 |
| ATTO-2306 (IL-13/IL-31 bispecific) | Atopic dermatitis, CSU, PN | antibody | Pre-clinical |
| ATTO-1091 (TL1A/IL-23/integrin a4b7 trispecific Fc-fusion) | Inflammatory bowel disease | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.